JMT101 Injection

DRUG3 trials

Sponsors

Shanghai JMT-Bio Inc.

Conditions

Harboring EGFR Common MutationLocal Advanced or Metastatic NSCLCPatients Who Have Experienced Treatment Failure at Least Second-line ChemotherapyRecurrent or Metastatic Nasopharyngeal Cancer

Phase 2

JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

Active, not recruitingNCT06391944

Shanghai JMT-Bio Inc.Harboring EGFR Common Mutation, Local Advanced or Metastatic NSCLC

Start: 2021-11-21End: 2026-11-21Updated: 2024-04-30

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

Not yet recruitingNCT06892431

Shanghai JMT-Bio Inc.Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy, Recurrent or Metastatic Nasopharyngeal Cancer

Start: 2025-04-01End: 2027-04-30Target: 150Updated: 2025-03-25

Phase 3

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Not yet recruitingNCT06380348

Shanghai JMT-Bio Inc.Local Advanced or Metastatic NSCLC

Start: 2024-04-26End: 2028-03-26Target: 398Updated: 2024-04-23